Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 657

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Toni Choueiri talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the biomarker analysis from the JAVELIN Renal 101 trial which observed avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).

He reports that PD-L1 as a biomarker was a negative prognostic indicator in patients who received sunitinib and didn't impact the benefit from avelumab plus axitinib.

Dr Choueiri explains however that high CD8 was associated with high progression free survival in the combination arm and the opposite in patients who received sunitinib.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation